Guided Therapeutics Reports $1.0 Million Net Loss in Q1 2026, Focuses on LuViva Device Commercialization

Guided Therapeutics, Inc. reported a net loss of $1.0 million for the first quarter of 2026, compared to a net loss of $463,000 in the same period of 2025. The company did not generate any revenue during the quarter, maintaining a consistent trend from the previous year. Operating expenses totaled $302,000, a decrease from $414,000 in the prior year, primarily due to reduced research and development costs. The company’s accumulated deficit increased to approximately $158 million as of March 31, 2026, reflecting ongoing operational challenges.

The company’s financial position showed a working capital deficit of approximately $5.1 million, with total assets amounting to $1.6 million, up from $1.3 million at the end of 2025. Cash and cash equivalents increased to $369,000 from $63,000, largely due to proceeds from warrant exercises and the issuance of notes payable. However, total liabilities rose to $6.8 million, compared to $7.3 million at the end of the previous fiscal year, indicating ongoing financial strain.

In terms of strategic developments, Guided Therapeutics is focused on the commercialization of its LuViva non-invasive cervical cancer detection device. The company is actively pursuing regulatory approvals in the U.S. and China, with plans to file clinical results with the FDA in the second quarter of 2026. The company has also received purchase orders from Turkey and Indonesia, which are expected to generate approximately $200,000 in revenue for 2026, contingent upon regulatory approvals and customer payments.

Operationally, the company has made progress in its clinical trials, having enrolled approximately 480 patients for the FDA application, with no reported adverse events. However, the company continues to face challenges in generating sales, as demand for LuViva is contingent on regulatory approvals that have yet to be secured. The company’s management has indicated that it expects to continue incurring losses as it invests in product development and marketing efforts.

Looking ahead, Guided Therapeutics anticipates needing approximately $2.4 million to fund its operations over the next 12 months, primarily for research and development and regulatory activities. The company is exploring various avenues for raising capital to support its ongoing efforts, but it acknowledges the uncertainty surrounding its ability to secure sufficient funding. If capital cannot be raised, the company may need to curtail operations, which could significantly impact its future viability.